ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

In Brief: Sparano Named Vice Chair of ECOG-ACRIN

May 17, 2013

Cervical Screening Should Emphasize Older Women, ASP Members Told

March 14, 1986

GM Downsizes “Nobel Prize” For Cancer; Bristol Ends Medical Research Grants and Awards Program.

June 23, 2006

NCI Programs: Institute To Expand Career Development, Training Grants

December 18, 1998

NCAB Action On Diet FIT “Not Cavalier,” Chairman Korn Says

November 10, 1989

Study Finds 4-20% Of Those With HTLV-3 Develop AIDs Within 32 Months Or Less

August 2, 1985